Background: Great conflict in the treatment of prostate cancertends to castration-resistant prostate cancer cases. Unfortunately,most of the patients experience some degree of androgenindependency even after two years of starting routinetreatments. Recent developments in personalized medicine inadvanced cancer treatment, opened new windows in to surveywhom struggling with prostate cancer, particularly castrationresistantpatients. Nowadays, a great deal of attention directedtowards specialized treatments which focus on interacting thegenes whose activity tends to grow in cancer. Using siRNAscapable the scientists to manipulate the gene activity. Due tosiRNA instability, its widespread use as systemic treatment incancer patients is still need more overview. On the other hand,for using the siRNAs as treatment reagents, must be ensured tobe released only in the target tissues. The capability of nanoparticlesin carrying and releasing drugs in target organs motivatedthe hypothesis in which siRNAs will be stabilized inconjunction with nanoparticles and then it would be expected tobe gradually released in the target tissues. In the view of the factthat Metal concentration of zinc in prostate cells is ۸۰۰-۱۶۰۰times greater than in other body cells, applying zinc nanoparticlesto carry and deliver drugs to the target tissue appears to bea reliable method.Materials and Methods: Zinc oxide nanoparticles were synthesizedby sol-gel method using zinc acetate and methanol as precursors.In the preparation, ۱۶ g of zinc acetate was dissolved in۱۱۲ ml of methanol. After ۱۰ minutes magnetic stirring at roomtemperature. Nano zinc oxide was washed several times withdouble distilled water to remove the byproducts. After washing,the ZnO nanoparticles were dried at ۸۰◦C in hot air oven withconstant stirring for ۵ hours.The resultant powder was annealedat ۵۰۰◦C for ۵ hours. The final product ZnO nanoparticles wereinvestigated by X-Ray Diffraction (XRD), Fourier-transforminfrared spectroscopy (FT-IR), Scanning Electron Microscope(SEM),and Cell viability was measured after ۳, ۵ and ۷ daysusing the MTS assay in PC۳M cells-highly malignant prostatecancer cell lines (for minimum toxicity to healthy cells fromZnO without conjugated drug) respectively.Results: Results from recent study shows a typical XRD patternof ZnO nanoparticles, the average crystal size of synthesizednanoparticles was calculated and FT-IR peak at ۴۱۷.۵۲cm-۱ indicated characteristic absorption bands OF ZnO nanoparticles.The SEM image shows that ZnO nanoparticles preparedin this study are spherical in shape. Using MTS assay,it has been shown that PC۳M cell viability were intact whentreated ZnO with a concentration of ۳۵ μg/ml. On the otherhand, Forootan,et al studies revealed that delivering siRNAs byatelocollagen could reduce the prostate cancer progression inmice model.Conclusion: Up to the finding of this study we decided tomake zinc nanoparticles and charge them with siRNA with theaim of applying them to cancerous cells. This study focusedon fabrication and characterization ZnO-NPs for the biomedicalapplications and drug delivery to improve their targetingand cytotoxicity against cancer cells and minimum toxicity tohealthy cells.